Why Is AstraZeneca plc Still Trading At A Premium To GlaxoSmithKline plc?

Roland Head asks why AstraZeneca plc (LON:AZN) continues to trade at a premium to GlaxoSmithKline plc (LON:GSK), following the failed Pfizer takeover bid.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The dust has now settled on Pfizer’s failed attempt to takeover AstraZeneca (LSE: AZN) (NYSE: AZN.US), but at 4,340p, the UK firm’s share price remains at a 14% premium to its pre-bid level of around 3,800p.

AstraZenecaWhat’s more, AstraZeneca’s forecast P/E of 17.5 puts it at a premium to its UK peer GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US), which trades on a forecast 2014 P/E of just 15.

Why is AstraZeneca’s valuation still so high?

One explanation could be that the market is pricing in a repeat visit from Pfizer later this year, after the six-month wait period has expired. That’s possible, although it’s hard to see the logic — political will in the UK and US is likely to remain against Pfizer, and unless the US firm offers more money, the end result is likely to be the same.

Should you invest £1,000 in Tullow Oil Plc right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Tullow Oil Plc made the list?

See the 6 stocks

A second possible explanation could be that Pfizer’s advances have forced AstraZeneca to reveal new information about its product pipeline that have materially increased its valuation.

However, while it’s certainly true that AstraZeneca has embarked on a major PR offensive to talk up its sales prospects, nothing material seems to have changed. Analysts’ consensus earnings forecasts for the next couple of years have actually edged lower over the last month.

In contrast, during the same period, Glaxo has sold its portfolio of oncology drugs to Swiss pharma firm Novartis for $16bn, announced a £4bn capital return to shareholders and spent $5.25bn on acquiring a portfolio of vaccines that should help it consolidate its dominant position in this sector.

Most recently, Glaxo has announced a new oncology joint venture that could result in a further lucrative spin-off in years to come.

What about fundamentals?

I’ve already touched on AstraZeneca’s premium P/E rating, but a closer look at the firm’s financials reveals several even less appealing figures:

  AstraZeneca GlaxoSmithKline
Return on Capital Employed (ROCE) 8.0% 24.7%
Operating margin 14.4% 26.5%
Prospective yield 3.9% 5.2%

Source: Company reports, Reuters consensus forecasts

For the record, I believe AstraZeneca is a great company and will deliver solid long-term returns to shareholders — but so is GlaxoSmithKline, and Glaxo is currently delivering attractive returns to shareholders, such as the £4bn capital return planned for next year, which equates to around 82p per share.

AstraZeneca shares are up 32% on one year ago, while GlaxoSmithKline’s share price is down by 5%. I don’t think that’s a fair assessment of the two firms’ relative progress over that time, which is why I would buy Glaxo today, but not AstraZeneca.

Should you invest £1,000 in Tullow Oil Plc right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets.

And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Tullow Oil Plc made the list?

See the 6 stocks

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> Roland owns shares in GlaxoSmithKline but not in any of the other companies mentioned in this article. The Motley Fool has recommended shares in Glaxo.

More on Investing Articles

Investing Articles

2 investment trusts to help investors become Stocks & Shares ISA millionaires

One of the biggest challenges for new Stocks and Shares ISA investors is which investments to make. Dr James Fox…

Read more »

Investing Articles

The Greggs share price has plummeted for good reason! It’s now a proper dividend stock

Dr James Fox explores whether the beaten-down Greggs share price represents a potential buying opportunity or a value trap.

Read more »

Working from home due to social distancing
Investing Articles

A year ago, £10,000 in Tesco shares — at today’s price — is now worth…

Tesco's provided solid investor returns since April 2024 thanks to strong share price gains and healthy dividends. Can it keep…

Read more »

Investing Articles

Just released: our 3 top small-cap stocks to consider buying in April [PREMIUM PICKS]

Small-cap shares tend to be more volatile than larger companies, so we suggest investors should look to build up a…

Read more »

Investing Articles

Here’s why Tesla stock just rocketed 22.7%! Is it time to buy?

This writer wonders whether the news that sent Tesla stock soaring yesterday is a true gamechanger for the electric vehicle…

Read more »

Investing Articles

2 quality UK stocks to consider buying as share prices rally

With UK stocks moving higher, it might look as though investors with cash on hand have missed their chance. But…

Read more »

Investing Articles

How much £10,000 invested in Lloyds shares is forecast to be worth in 12 months

Harvey Jones is looking past today's stock market volatility to see where Lloyds shares may stand in a year's time.…

Read more »

Investing Articles

How Warren Buffett stays ahead of the stock market

When share prices fall, everyone suddenly wants to be like Warren Buffett. But what’s the secret to the Berkshire Hathaway…

Read more »